1. In Vivo

St. Jude Sees New Techs Keeping It One Step Ahead Of The Field

 
• By Ashley Yeo

Improving outcomes, reducing costs, and cutting readmissions are front and center for St. Jude Medical as it moves into new areas of cardio technology that suit the changing needs of both providers and patients.

A few weeks ago, St. Jude Medical Inc. marked the one-year anniversary of its acquisition of Atlanta, GA, company CardioMEMS Inc., developer of the CardioMEMS HF System, which became the first FDA-approved heart failure monitor that is proven to significantly reduce HF hospital admissions and improve quality of life in New York Heart Association (NYHA) class III patients.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment

 
• By David Wild

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.

Richard DiMarchi On The GLP-1 Revolution: An Overnight Success After 40 Years

 
• By Andrew Warmington

As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.

Rising Leaders 2025: João Ribas On Building At The Intersection Of Science And Business

 
• By Jo Shorthouse

João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.